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http://dx.doi.org/10.1016/j.stemcr.2016.05.011SUMMARYAwidely shared view reads thatmesenchymal stem/stromal cells (‘‘MSCs’’) are ubiquitous in human connective tissues, can be defined by
a common in vitro phenotype, share a skeletogenic potential as assessed by in vitro differentiation assays, and coincide with ubiquitous
pericytes. Using stringent in vivo differentiation assays and transcriptome analysis, we show that human cell populations from different
anatomical sources, regarded as ‘‘MSCs’’ based on these criteria and assumptions, actually differ widely in their transcriptomic signature
and in vivo differentiation potential. In contrast, they share the capacity to guide the assembly of functionalmicrovessels in vivo, regard-
less of their anatomical source, or in situ identity as perivascular or circulating cells. This analysis reveals that muscle pericytes, which are
not spontaneously osteochondrogenic as previously claimed, may indeed coincide with an ectopic perivascular subset of committed
myogenic cells similar to satellite cells. Cord blood-derived stromal cells, on the other hand, display the unique capacity to form cartilage
in vivo spontaneously, in addition to an assayable osteogenic capacity. These data suggest the need to revise current misconceptions on
the origin and function of so-called ‘‘MSCs,’’ with important applicative implications. The data also support the view that rather than a
uniform class of ‘‘MSCs,’’ different mesoderm derivatives include distinct classes of tissue-specific committed progenitors, possibly of
different developmental origin.INTRODUCTION
The anatomical identity of mesenchymal stem/stromal
cells (‘‘MSCs,’’ the current ‘‘jargon’’), their phenotype, dis-
tribution in different tissues, lineage, physiological func-
tions, and biological properties represent one of the most
controversial and confusing areas in stem cell biology. At
this time, two quite distinct descriptions of ‘‘MSCs’’ are
found in the literature. One, which emanates from 50
years of widely reproduced experimental work in vivo,
sees ‘‘MSCs’’ as the same biological object previously
known as cultured bone marrow stromal cells (BMSCs);
these cells are unique to bone marrow (BM), and include
a subset of physically identifiable clonogenic, multipotent,
self-renewing progenitors of skeletal tissues, and skeletal
tissues only (Bianco et al., 2013). This progenitor is en-
dowed with the unique capacity to organize the hemato-
poietic microenvironment and the hematopoietic stem
cell niche (Bianco, 2011; Friedenstein et al., 1982). The
other view sees ‘‘MSCs’’ as progenitors of multiple tissuesStem
This is an open access article under the Cbeyond the range of skeletal tissues, such as skeletal muscle
(Caplan, 1991, 2008; Crisan et al., 2008). The demonstra-
tion that ‘‘MSCs’’ are perivascular cells in BM (Sacchetti
et al., 2007) was later extrapolated to claim that in virtually
all tissues, pericytes (identified as CD34/CD45/CD146+
cells) would represent ‘‘MSCs’’ (Caplan, 2008; Crisan
et al., 2008). Hence, these broadlymultipotent progenitors,
essentially defined by in vitro assays (Dominici et al., 2006;
Pittenger et al., 1999) that are neither specific nor stringent,
would be found in multiple tissues well beyond BM (e.g.,
skeletal muscle, fat, placenta, umbilical cord) (Caplan,
2008; da Silva Meirelles et al., 2006).
Definition of the origin, anatomy, biological properties,
and function of so-called ‘‘MSCs’’ has obvious implications,
both for understanding their biology and for their use in
potential therapies. Notably, assuming that ‘‘MSCs’’ with
identical differentiation properties can be isolated from
virtually every tissue would imply that multiple tissues
are equally suitable cell sources for the regeneration ofmul-
tiple tissues. On the other hand, the assumption thatCell Reports j Vol. 6 j 897–913 j June 14, 2016 j ª 2016 The Authors. 897
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‘‘MSCs’’ are the ex vivo counterpart of pericytes would lend
support to the view that a number of non-progenitor func-
tions (Bianco et al., 2013) of ‘‘MSCs’’ (anti-inflammatory,
immunomodulatory, trophic), claimed to be of major
import for therapy of a number of unrelated disorders (Ca-
plan and Correa, 2011), are traceable to an identifiable and
ubiquitous in vivo cell type. Nonetheless, pericytes are only
defined by anatomy, and currently no experimental data
support the notion that they represent a distinct lineage
(Armulik et al., 2011; Diaz-Flores et al., 2009). In addition,
their role in tissue injury and repair is pleiotropic and
spans multiple distinct processes including inflammation;
furthermore, their participation in the repair of tissues
(e.g., through the formation of scar tissue) does not neces-
sarily coincide with a regenerative function.
We previously identified a minimal surface phenotype
suited not only to enrich the archetypal human ‘‘MSCs’’
in uncultured BM cell suspensions, but also to correlate
their ex vivo-assayed clonogenic capacity with their
in situ identity and in vivo fate following transplantation
(Sacchetti et al., 2007). As applied to the study of BMSCs,
this led to identification of ‘‘MSCs’’ as subendothelial, peri-
vascular CD146+ cells on BM sinusoids, and also provided
evidence for their self-renewal in vivo, which had long
been themissing evidence to support the claim that BMSCs
indeed include a subset of bona fide stem cells, rather than
multipotent progenitors (Bianco et al., 2013; Sacchetti
et al., 2007). Using an identical approach to prospectively
isolate ‘‘MSCs’’ from a variety of non-BM tissues, Crisan
and co-workers later reported that a ubiquitous population
of highly myogenic and skeletogenic CD146+ cells, coin-
ciding with ‘‘MSCs,’’ is found in association with microves-
sels of skeletal muscle and other tissues, lending support to
the view of pericytes as a uniform, widely distributed pop-
ulation of cells that can be explanted and cultured as
‘‘MSCs’’ (Caplan, 2008; Caplan and Correa, 2011; Crisan
et al., 2008). However, striated muscle and skeletal lineages
such as bone, cartilage, and marrow fat diverge early
in development, and no common progenitor of bone
and muscle is found in prenatal life past the time of
sclero-myotome specification in somites (Applebaum and
Kalcheim, 2015). The notion of a common postnatal
progenitor of bone and muscle, therefore, would be at
odds with established tenets in developmental biology
(Bianco and Robey, 2015).
We show here that MCAM/CD146-expressing stromal
cells from different human tissues diverge radically from
their BM counterparts in differentiation potency and
transcriptional profile, reflective of their different develop-
mental origin. While BM-derived ‘‘MSCs’’/pericytes are
natively skeletogenic but not myogenic, muscle-derived
‘‘MSCs’’/pericytes are inherentlymyogenic but not natively
skeletogenic, and appear to represent a subset of cells with898 Stem Cell Reports j Vol. 6 j 897–913 j June 14, 2016functional features of satellite cells, but not their
characteristic anatomical location. We further show that
prenatal, cord blood-borne ‘‘MSCs’’ in turn exhibit a
distinct transcriptional and potency profile, and an
inherent cartilage commitment, which diverge markedly
from that of postnatal BM-derived ‘‘MSCs.’’ Finally we
show that, irrespective of the postnatal tissue source of
theseperivascular cells or fromfetal blood, these committed
progenitors of mesoderm derivatives can associate with
nascent blood vessels (BVs) in vivo and be recruited to a
mural cell fate. However, a systemof committed and self-re-
newing progenitors with distinct native potency, and not a
uniform, equipotent class of ‘‘MSCs’’ is associated with
microvascular walls in postnatal mesoderm-derived tissues
as reported previously for bone/marrow (Sacchetti et al.,
2007), and as shown herein for muscle. Pericyte recruit-
ment frompreexisting local progenitors is a simpledevelop-
mental process that explains the very existence of such pro-
genitors in postnatal life and their tissue-specific properties.RESULTS
The Phenotype of ‘‘MSCs’’ In Vitro Does Not Reflect
Cell Identity and Function
Stromal cell strains were established from four different tis-
sue sources: BM, skeletal muscle (MU), periosteum (PE),
and perinatal cord blood (CB). For all postnatal tissue
sources, clonogenic cells were prospectively isolated based
on aminimal surface phenotype as previously described for
human BMSCs (CD34/CD45/CD146+); colonies of CB
stromal cells were established as described previously
(Kluth et al., 2010; Kogler et al., 2004). Of note, CD146
identified a clonogenic subset in MU (presented below)
and PE (data not shown), as it does in BM. Multiclonal
strains derived from growth of the originally explanted
cells were then expanded under identical basal culture con-
ditions that do not support the growth of endothelial cells
or induce differentiation. All resulting cell strains exhibited
the canonical in vitro cell-surfacemarkers regarded as char-
acteristic of ‘‘MSCs’’ (Figure 1A).
To determine the specificity and functional significance
of the cell-surface phenotype of ‘‘MSCs,’’ widely regarded
as a defining feature of ‘‘MSCs’’ across tissues, we performed
gene-expression profiling using Affimetrix technology.
Both unsupervised hierarchical clustering (Figure 1B) and
principal component analysis (Figure 1C) revealed that
gene-expression profiles of ‘‘MSCs’’ are clearly separated
by an ‘‘origin’’ factor, indicating the lack of specificity
and sensitivity of the widely used ‘‘minimum’’ surface
phenotype. ANOVA-based supervised analysis selected
1,614 class-specific, differentially expressed genes (Table
S1) showing a fold difference >3 and a false discovery rate
Figure 1. Cell Surface and Transcriptomic Comparison of ‘‘MSCs’’
from Different Tissues
(A) Fluorescence-activated cell sorting (FACS) analysis of multi-
clonal BM (bone marrow), MU (muscle), PE (periosteum) and CBq value of <0.05. While perinatal CB cells are characterized
by over-representation of genes related to proliferation and
cell-cycle regulation (Figures 2A–2C), the postnatal MU
cells are characterized by over-representation of tissue-spe-
cific genes related to their tissue origin (Figures 2D and 2E),
including the myogenic transcription factor, PAX7 (Fig-
ure S1A). Tables S2 and S3 show the first 100 enriched
gene sets for CB andMU classes, respectively, while Figures
2A1–2E1 show enrichment plots and heatmaps for selected
gene sets. The over-represented gene sets coming from
gene set enrichment analysis (GSEA) (Subramanian et al.,
2005) support the notion that prospectively purified CB
‘‘MSCs’’ are highly proliferative, since the majority of
gene sets enriched in this phenotype are related to prolifer-
ation, S phase, RNA and DNA synthesis, or DNA repair. On
the other hand, prospectively purified MU ‘‘MSCs’’ are
clearly characterized by the over-representation of gene
sets specifically related to either muscle development or
muscle differentiated function (muscle contraction, mus-
cle development, and energy metabolism). PE and BM
expression profiling was analyzed in the same way, but
no gene sets were statistically significantly enriched in PE
versus CB, BM, and MU, or in BM versus PE, CB, and MU.
However, a number of genes enriched in BM and PE cells
was identified (Table S4). Furthermore, genes associated
with hematopoietic support, a defining feature of BM cells,
were over-represented in BM cells compared with CB, MU,
and PE cells (Figure S2A).‘‘MSCs’’ from Different Sources Have Radically
Different Differentiation Properties
BM ‘‘MSCs,’’ prospectively sorted as CD34/CD45/
CD146+ and grown under basal conditions that do not
induce differentiation, regularly form bone and establish
the hematopoietic microenvironment when transplanted
heterotopically using an osteoconductive carrier (Sacchetti
et al., 2007) (Figure 3Aa). Cells sorted based on the same
phenotype from BM and other tissues, including MU,
were later reported to be highly myogenic both in vitro(cord blood) cells (representative of one from least three indepen-
dent experiments). All strains express the canonical in vitro
phenotype of ‘‘MSCs’’ and CD146 (isotype controls indicated in gray).
(B and C) Unsupervised clustering of gene-expression profiling data
of CD146+ cells purified from BM, CB, MU, and PE (three indepen-
dent samples for each cell type). Unsupervised analysis was per-
formed to investigate whether there was evidence for native
groupings of samples based on correlations between gene-expres-
sion profiles. Results of the hierarchical clustering (B) and the
principal component analysis (C) revealed that gene-expression
profiles of CD146+ cells are clearly separated by the origin factor.
See Supplemental Experimental Procedures for further details of
statistical analyses.
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Figure 2. Enrichment Plots and Heat Maps of Selected
Gene Sets for Cord Blood- and Muscle-Derived CD146+
Cells
(A–C1) Prenatal CB (cord blood) ‘‘MSCs’’ are characterized
by the over-representation of many genes related to pro-
liferation and cell-cycle regulation.
(D and E) Postnatal MU (muscle) ‘‘MSCs’’ are characterized
by the over-representation of tissue-specific genes related
to their tissue origin, specifically by genes regulating
muscle contraction, muscle development, and energy
metabolism. The over-represented gene sets from GSEA
showed that prenatal CB CD146+ cells are enriched in gene
sets related to proliferation S phase, RNA and DNA syn-
thesis, or DNA repair.
For each enriched gene set, the gene expression is also
represented as a blue-pink o’gram in (A1), (B1), and (C1)
(CB ‘‘MSCs’’), and (D1) and (E1) (MU ‘‘MSCs’’). See Supple-
mental Experimental Procedures for further details of
statistical analyses.
900 Stem Cell Reports j Vol. 6 j 897–913 j June 14, 2016
Figure 3. In Vivo Transplantation of CD146+ ‘‘MSCs’’ Derived from Different Tissues
(A) In vivo osteogenic differentiation of BM (bone marrow, a), MU (muscle, b), PE (periosteum, c), and CB (cord blood, d) cells
(representative results of one from at least three transplants). Sirius red (columns 1 and 3) stains bone (labeled b) intensely due its high
collagen content. Polarized light (columns 2 and 4) shows the distribution of Sirius red-stained collagen fibers in bone. When CD146+ ‘‘MSC’’
strains were transplanted, using the same in vivo assay with hydroxyapatite/tricalcium phosphate (HA/TCP) as a scaffold (labeled s),
osteogenic potential was restricted to BM-, PE-, and CB-derived cells. MU cells regularly failed to form any histologically identifiable bone.
(legend continued on next page)
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and in vivo, in addition to sharing the ability to differen-
tiate in culture toward skeletal lineages (Crisan et al.,
2008), based onwidely used artificial differentiation assays.
In vitro, Alizarin red S and von Kossa staining cannot
distinguish between dystrophic calcification induced by
dead and dying cells versus matrix mineralization, or cal-
cium phosphate precipitates generated by cleavage of
b-glycerophosphate (a component of osteogenic medium)
by alkaline phosphatase (ALP), which is expressed by
many types of stromal cells. In vivo transplantation of
MU ‘‘MSCs’’ of identical surface phenotype as BM
‘‘MSCs’’ revealed no spontaneous in vivo osteogenic poten-
tial (Figure 3Ab). Likewise, cells established in culture from
skin, adipose tissue, and amniotic fluid, all sharing the
in vitro phenotype of ‘‘MSCs,’’ regularly failed to form
any histology-proven bone (Figure S2), whereas PE
‘‘MSCs’’ did form bone in vivo, as previously reported (Sac-
chetti et al., 2007; Figure 3Ac). Using the same in vivo assay
and carrier, CB ‘‘MSCs’’ formed histology-proven bone of
donor origin (Figure 3Ad, human Lamin A/C-positive oste-
ocytes, not shown). Surprisingly, they also generated
Safranin O+, Alcian blue+, COL2+ hyaline cartilage inter-
mingled with bone in the same assay (three of three strains
from different donors, and one of three single colony-
derived strain), but never established a hematopoietic
microenvironment (Figures 3Ba–3Bh). This result was
unique, as previously we have never seen BM ‘‘MSCs’’
make cartilage in this ceramic-based assay. Failure to
generate cartilage under these conditions has been inter-
preted as a need for a hypoxic environment for chondro-
genesis in vivo, which is not provided in an open
transplantation system permissive for vascularization.
While hypoxia undoubtedly contributes to chondrogene-
sis (as in fracture callus formation; e.g., Hirao et al.,
2006), our results suggest that there are also cell-intrinsic
factors at play in CB-derived chondrogenesis based on their
more primordial, fetal origin (Bianco and Robey, 2015).
Themyogenic capacity of the same cell strains was tested
under stringent conditions (i.e., in the absence of exoge-
nous myoblasts in vitro or endogenous myoblasts in vivo
[Sherwood et al., 2004], of demethylating agents such as
5-azacytidine [Wakitani et al., 1995]). MU ‘‘MSCs’’ cultured
without myoblasts in canonical myogenic conditions (2%
horse serum on Matrigel) (Dellavalle et al., 2007) readilyPE and CB ‘‘MSCs’’ formed bone, but never established a hematopoiet
hematopoietic microenvironment (asterisks in a, third panel), which i
such as megakaryocytes and granulocytes, as seen under high-power
(B) Clonal strains of CB CD146+ ‘‘MSCs’’ transplanted using HA/TCP as
plants) generated abundant bone and hyaline cartilage (labeled c). a,
their proteoglycan content) and Fast green (stains bone matrix deep
eosin, cartilage stains light blue; d: Alcian blue (stains cartilage ma
immunohistochemistry. Scale bars represent 700 mm (a), 150 mm (b–
902 Stem Cell Reports j Vol. 6 j 897–913 j June 14, 2016and efficiently generated myotubes in culture, whereas no
myogenesis was observed under identical conditions with
non-MU-derived stromal cells (Figure 4A). With these
non-MU ‘‘MSCs,’’ myotubes could only be obtained in co-
cultures with myoblasts (mouse C2C12 cells). Notably, the
vast majority of nuclei incorporated in the newly formed
myotubes were murine, indicating that human non-MU
‘‘MSCs’’ contribute only marginally to myogenesis in vitro
even in permissive co-culture differentiation assays (data
not shown). In cultures of MU CD146+ cells (Figure 4C)
highly efficient myogenesis was observed, even in colonies
established by singleCD146+ cells (Figure 4B), and occurred
spontaneously as the colonies became dense (13/32; 41%)
as observed with bona fide myoblasts (Figure 4D).
Local transplantation of CD146+ BM, PE, or CB cells into
cardiotoxin (CTX)-injured tibialis anterior muscle of SCID/
beige (Figure 5A) or SCID/mdxmice (datanot shown) (Della-
valle et al., 2007) failed to contribute to regeneratingmuscle.
Incontrast,CD146+MUcells revealed anefficient incorpora-
tion of donor nuclei (Figures 5B; Tables S5A and S5B), and
expression of human muscle proteins in regenerating myo-
fibers (Figure 5C [CD56], Figure 5D [Dystrophin 2, Spectrin],
and Table S5C). Subsequently, enzyme-released cells of the
harvested injected TA were used to perform secondary MU
colony-forming efficiency (CFE) assays (Supplemental
Experimental Procedures; Figure S3). Human cells were iso-
lated based on hCD44, hCD90, and hCD146 expression
and, after brief expansion (2 weeks), reanalyzed by fluores-
cence-activated cell sorting (FACS) for hCD44, hCD90, and
hCD146 expression. The human cells were then isolated by
MiniMacs (Miltenyi) and were replated in culture at clonal
density. All colonies harvested at 2 weeks were uniformly
positive for hCD146 and negative for hCD56 and hCD34,
demonstrating that hCD146+ pericytes isolated from the in-
jected muscle were the source of the secondary MU colony-
forming unit-fibroblasts (CFU-Fs), indicative of self-renewal.
The canonical in vivo muscle regeneration assay relies in
large part on fusion between donor cells and host myo-
blasts, which implies recruitment of the former to a newly
forming myotube where they will be reprogrammed by
host myogenic factors. Even though CB, PE, and BM cells
failed to differentiate under these conditions, a more strin-
gent in vivo myogenesis assay requires the exclusion of
such recruitingmyoblasts. To this end, we suspended equalic microenvironment. BM ‘‘MSCs’’ formed bone and established the
s assessed by determining the presence of extravascular blood cells
microscopy (not shown). Scale bars represent 700 mm.
a scaffold (representative results from one of at least three trans-
b, f–h: Safranin O (stains chondrocytes and cartilage orange due to
green-blue); c: H&E, whereby unlike bone which stains pink with
trix); e: anti-type II collagen (an essential cartilage component)
e), 40 mm (f), 15 mm (g), and 21 mm (h).
Figure 4. In Vitro Myogenic Assay of CD146+ ‘‘MSCs’’ Derived from Different Tissues
(A) Conventional in vitro differentiation assays were conducted using multiclonal ‘‘MSCs’’ from BM (bone marrow, a), PE (periosteum, b), CB
(cord blood, c), and MU (muscle, d) cells, which were first expanded on plastic with 20% FBS, and then replated on Matrigel with 2% horse
serum (representative results from one of at least three independent experiments). With MU CD146+ ‘‘MSCs,’’ extensive formation of
myotubes expressing specific myogenic markers were observed. No myogenic differentiation was observed with any non-MU-derived cell
strain. MyHC, myosin heavy chain. Scale bar represents 120 mm.
(B) Freshly isolated MU CD146+ cells were plated at clonal density (1.6 cells/cm2, indicated in upper left corner). At clonal density, MU
CD146+ but not MU CD146 cells formed discrete fibroblastic colonies (arrows point to colonies, number of colonies formed indicated in
lower right corners, Giemsa stain) (representative results from one of least three independent experiments).
(C) Cell morphology in single colonies generated by CD45/CD34/CD146+ muscle-derived clonogenic cells at 6 days (scale bar, 40 mm)
and 14 days (scale bars, 300 mm and 40 mm) in culture, in 20% serum, and on plastic (results from one experiment).
(D) Three such colonies of MU cells, one at low power (scale bar, 300 mm) and two at high power (scale bar, 60 mm), at 28 days without
passage. With time and without passage, colonies become dense and 13 of 32 (41%) underwent spontaneous differentiation. Multinu-
cleated myotubes are obvious after Giemsa staining (arrows).numbers of MU (transduced to express a cell-surface GFP
label), BM, or CB cells with identical surface phenotype,
grown in culture under identical basal conditions that did
not induce differentiation, in growth factor-reduced Matri-
gel, and injected the resulting suspension into the epifas-
cial space of the back of SCID/beige mice. Plugs harvested
at 3 weeks demonstrated that MU cells had generated
myotubes, myofibers, and a unique spheroidal syncytia ex-
pressing a differentiated muscle phenotype (Figure 5E, des-
min, MyHC, CD56). The myosac phenotype may result
from spontaneous contraction of the myotube poorlyadhering to the substrate and obviously not constrained
by tendons. BM cells, while remaining viable, did not
generate bone, cartilage, or muscle. CB cells, which formed
bone and cartilage upon transplantation with an osteocon-
ductive carrier, generated hyaline cartilage but not bone in
Matrigel (Figure 5F).
MU CD146+ Cells Are Perivascular, Committed
Myogenic Progenitors
These data revealed a strong, spontaneous myogenic capac-
ity specific for MU CD146+ cells, fully consistent with theStem Cell Reports j Vol. 6 j 897–913 j June 14, 2016 903
(legend on next page)
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highexpressionofmyogenic regulatory factors andgenes re-
flecting the differentiated function of muscle (Figure S1B).
Cell sorting, immunolocalization, and CFE assays identified
MU CD146+ cells as distinct from CD56+/CD146 satellite
cells and CD34+/CD146+ endothelial cells (Figure S4 and
Tables S6A–S6C). Inculturesestablished fromhighlypurified
CD56/CD146+ cells, CD146 expressionwas turned off over
time while expression of CD56, PAX7, ALP (previously re-
ported to be a pericyte marker in muscle; Dellavalle et al.,
2007], MyoD, Myogenin were turned on (Figures 6A and
S1C). Only a small subset of clonogenic, myogenic CD146+
cells co-expressed ALP (Figure 6B and Table S6D), and
myogenic cells were highly enriched in the CD146+/ALP
fraction (Figure 6C). In situ, ALP and CD146 were expressed
in amutually exclusive fashion in precapillary arterioles and
postcapillary venules, respectively, suggesting that the
venous compartment represents the largest repository of
perivascular CD146+ cells that can be assayed as myogenic
progenitors (Figure 6D). Immunolocalization studies further
revealed the presence of a relatively rare population of
adventitial cells expressingmuscle regulatory factor proteins
(PAX3, PAX7) in postcapillary venules (Figure 6E). Freshly
isolated MU CD146+ cells also co-expressed PAX7 by FACS
(Figure 6F) and by RT-PCR (Figure S1B).
Generation of Perivascular Cells from Different Types
of Stromal Cells In Vivo
In heterotopic transplants made with osteoconductive car-
riers, BM-derived skeletal stem cells can guide and organizeFigure 5. Intramuscular and Ectopic In Vivo Transplantation of C
(A) Human BM (bone marrow), PE (periosteum), and CB (cord blood)
injured muscle in SCID/beige mice after 4 weeks failed to contribute t
detected by anti-human Lamin A/C (red) (laminin, green). Scale bar
(B) Human CD34–/CD56–/CD146+ muscle-derived cells were injected i
SCID/beige mice, injured 1 day earlier by an intramuscular injection
expression of human Lamin A/C (red), were distributed to the interstiti
surface of myofibers (MF) in a satellite cell-like position (arrowheads
(C) Cells in a characteristic satellite cell-like position (arrowheads an
20 mm as indicated.
(D) Clusters of myofibers expressing human Dystrophin 2 and Spectri
beige/CTX-treated and SCID/mdx mice (DAPI: nuclear stain). Scale b
(E) In a heterotopic transplantation assay, human CD34–/CD56–/CD1
suspended in growth factor-reduced Matrigel (labeled matrigel in pa
back of SCID/beige mice, and harvested 3 weeks later. Extensive form
myogenic markers, Desmin (g and k), myosin heavy chain (MyHC, h an
and non-conventional muscle structures (f, red arrows, i–k) were obse
50 mm as indicated.
(F) No myogenic differentiation was observed with BM (stained blue w
and myofibers). In contrast, CB CD146+ ‘‘MSCs’’ spontaneously generate
Alcian blue in e, f [arrows]) when transplanted in Matrigel as a carrier
extensive cartilage differentiation observed.
All data shown are representative results from one of at least three in
150 mm, or 200 mm as indicated.the formation of BVs, with which a subset of them ulti-
mately associates (Sacchetti et al., 2007). To test the ability
of BM- and non-BM-derived progenitors to guide and orga-
nize nascent BVs under simplified conditions that bar the
formation of bone, we co-transplanted BM- and non-BM-
derived progenitors in Matrigel, along with human umbil-
ical vein endothelial cells (HUVECs). With cell-surface
GFP-labeled BM-derived progenitors, this resulted in the
formation of an extensive network of capillary-like BVs at
3 weeks. Their wall was composed of two cell layers: an in-
ner hCD34+ endothelial layer (red), and an outer, discon-
tinuous layer of mural cells (green) made by transplanted
BM progenitors, expressing CD146 and a-smooth muscle
actin (a-SMA) (Figure 7A). In transplants harvested at
8 weeks, extensive maturation of the BVwall was observed,
as indicated by the formation of thick-walled artery- and
vein-like BVs, with a multilayered GFP+, a-SMA+ smooth
muscle coat. The BVs were functional and perfused by
host blood (Figure 7A). Experiments performed with cell-
surface GFP-labeled MU CD146+ cells also resulted in the
formation of a capillary lattice, which was less extensive
than with BM CD146+ cells, but similarly well organized
(Figure 7B, quantitated in Figure S5). No obvious differenti-
ation of muscle structures were observed in these trans-
plants, at variance with transplants of MU CD146+ cells
without HUVECs, suggesting that the contribution to BV
formation and myogenesis could be alternative fates
dictated by endothelial cells. With CB CD146+ cells, again
the formation of functional BVs was observed. Strikingly,D146+ ‘‘MSCs’’ Derived from Different Tissues
derived cells in orthotopic transplantation into cardiotoxin (CTX)-
o generation of muscle cells or regenerating myofibers as would be
represents 75 mm.
ntramuscularly into the left tibialis anterior of 2-month-old female
of CTX. After 4 weeks transplanted human MU cells, identified by
um (arrows), but also below the basement membrane (green) on the
). Scale bars represent 10 mm, 15 mm, or 20 mm as indicated.
d arrow) express human CD56 (red). Scale bars represent 15 mm or
n were generated by MU cells by in vivo transplantation into SCID/
ar represents 350 mm.
46+ MU cells, transduced to express a cell-surface GFP label, were
nels) without HUVECs and injected into the epifascial space of the
ation not only of myotubes (a, b, and h) expressing human-specific
d i), and CD56 (j), but even of striated myofibers (c–e, black arrows)
rved (H&E, a–f). Scale bars represent 5 mm, 10 mm, 15 mm, 25 mm, or
ith H&E in a, b, arrows) or any non-MU cell strain (lack of myotubes
d hyaline cartilage (stained light blue with H&E in c, d [arrows] and
. No ingrowth of BVs into the Matrigel plug was associated with the
dependent experiments. Scale bars represent 15 mm, 20 mm, 30 mm,
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these BVs, lined by a continuous hCD34+ endothelial layer,
were coated by a thin layer of subendothelial CD146+
mural cells, and an outer coat of differentiated chondro-
cytes (Figure 7C), making these BVs a unique kind of carti-
lage-armored BV, not known to occur in natural tissues.
Knockdown of CD146 in cell-surface GFP-labeled BM pro-
genitors (as previously described by Sacchetti et al., 2007)
(Supplemental Experimental Procedures) partially inter-
fered with BV organization, resulting in BVs of irregular
size and shape, often devoid of a lumen, and devoid of a
mural cell coat (Figure S6). Due to the ability of BM, MU,
and CB cells to form perivascular cells, we examined the
transcriptome data (including PE cells, although not used
for this assay) for additional markers that are associated
with pericytes (e.g., Armulik et al., 2011). A variety of peri-
cyte markers were expressed by all four cell populations,
but the pattern of expression varied from one cell type to
another, consistent with their diverse developmental ori-
gins (Figure S7).DISCUSSION
A widely accepted view in the literature holds that ‘‘MSCs’’
can be defined by rather loose and non-specific in vitro
properties, and exhibit identical functional and differenti-
ation properties regardless of their tissue source. This view,Figure 6. Induction of CD56 Expression, Colony-Forming Efficien
‘‘MSCs,’’ and In Vivo Localization of ALP, CD146, and PAX 7
(A) Induction of the satellite cell marker, CD56, in cultures of CD34/
Red box indicates the population of CD146+/CD56 cells used to est
CD146- and ALP-expressing cells is detectable after 18 days in culture,
replating cultured CD146+/CD56+ cells at high density with 20% FBS, CD
detectable. By fluorescent immunocytochemistry, subconfluent cultur
blue nuclear stain, DAPI) (22 days in culture), and when replated at
staining) express myosin heavy chain (MyHC, red), co-localizing with
tiation (26–28 days in culture), CD146 expression is barely detectabl
(B) FACS of collagenase-released cell suspensions of muscle. Co-expres
CFE assay of FACS-sorted CD146/ALP+ cells and CD146+/ALP+ cell sub
cell densities. Numbers (upper left of each panel) indicate the numb
(C) When unsorted cell strains, sorted CD146+/ALP, CD146+/ALP+,
representative of one of at least three independent experiments, ***
density and induced to myogenic differentiation (2% horse serum on
specific myosin heavy chain (MyHC, red) are found in freshly sorted c
observed in cultures of CD146+/ALP+ cells. Scale bar represents 120 m
(D) Immunolocalization analysis of the distribution of CD146 and AL
arrow, upper left) were predominantly expressed in precapillary arte
dominantly expressed in large venules (v). Scale bars represent 100 m
(E) A subset of vascular-wall-associated cells was found to express PAX
MU. Immunoreactivity was distributed to the surface of myofibers
basement member (laminin, green), and to BV walls (V). Scale bars r
(F) Freshly isolated, uncultured CD146+ cells were found to co-expres
All data shown are representative results from one of at least three icomplemented by the notion that ‘‘MSCs’’ would coincide
with ubiquitous pericytes, was recently reinforced by the
claim that MU-derived pericytes would be both myogenic
and skeletogenic, and exhibit an in situ surface phenotype
similar to the one characteristic of BMSCs (i.e., of a skeletal
stem cell origin) (Bianco, 2014). We have shown here that
CD34/CD45/CD146+ ‘‘MSCs’’ isolated from different tis-
sues have inherently distinct transcriptomic signatures and
differentiation capacities. By gauging their native differen-
tiation potential with a variety of stringent differentiation
assays, we demonstrated that human BM CD146+ cells are
inherently geared to generate bone and BM stroma that
support hematopoiesis and include adipocytes, but are
not myogenic, and are not spontaneously chondrogenic
in vivo; MU ‘‘MSCs’’ with an identical cell-surface pheno-
type are not inherently skeletogenic, and are inherently
myogenic; and CB ‘‘MSCs’’ are notmyogenic, but are chon-
dro-osteoprogenitors most likely due to their fetal origin
(Bianco and Robey, 2015) and are the only kind of human
‘‘MSCs’’ ever shown to actually form cartilage consistently
in open heterotopic transplants in vivo, independent of
any ex vivo induction to cartilage differentiation as applied
in the widely used pellet culture assay. CB cells are unlike
other cells that are found in the umbilical cord, based on
their cell-surface markers, their ability to differentiate
into adipocytes and cartilage, and expression of associated
markers, and they have a distinct expression pattern ofcy and Myogenic Differentiation of FACS Sorted Muscle-Derived
CD56/CD146+ cells by FACS and fluorescent immunocytochemistry.
ablish the cultures. By FACS, co-expression of CD56 in a subset of
and the percentage of CD146+/CD56+ cells increases over time. Upon
146 expression is turned off, whereas CD56+ expressing cells remain
es express CD56 (green) and PAX7 (purple when colocalized with the
high density with 20% FBS, myotubes with numerous nuclei (DAPI
CD56 (green) resulting in yellow. At a terminal stage of differen-
e. Scale bars represent 60 mm or 250 mm as indicated.
sion of CD146 and ALP, in human MU cell suspensions before culture.
sets. CD146+/ALP+ and CD146/ALP+ cells were plated at different
er of cells plated/cm2.
and CD146/ALP+ total collagenase-released cells (bar graph is
p < 0.001 compared with CD146+/ALP cells) were plated at clonal
Matrigel), high numbers of myotubes expressing skeletal muscle-
ultures enriched in MU CD146+/ALP cells. Only rare myotubes are
m.
P expression in intact muscle revealed that while ALP cells (green,
rioles, CD146 cells (red, arrows, center and lower right) were pre-
m or 120 mm as indicated.
3 (red, left panel) and PAX7 (red, right panel) in intact adult skeletal
(MF) in a satellite cell-like position (arrowhead) underneath the
epresent 10 mm or 25 mm as indicated.
s the satellite cell marker, PAX7.
ndependent experiments.
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HOXgenes comparedwith other umbilical cord derivatives
(Bosch et al., 2012; Liedtke et al., 2010, 2016). BM- andMU-
derived clonogenic progenitors of mesoderm derivatives
are associated with BV walls in situ and include cells in a
position characteristic of mural cells/pericytes, but also
include vascular-wall cells that do not necessarily exhibit
anatomical features of pericytes proper, for example,
adventitial cells in muscular veins. More strikingly,
fetal chondro-osteoprogenitors that circulate in CB, by
definition, are neither associated with BV walls nor repre-
sent pericytes. The origin of these cells remains to
be elucidated. It is conceivable, however, that skeletal
progenitors located at sites of active skeletal growth can
accidentally spill over into the bloodstream. Nonetheless,
independent of their origin, native differentiation po-
tencies, gene-expression profiles, and in situ anatomical
positioning, perinatal and postnatal mesoderm progeni-
tors of different origins can dynamically associate with,
and organize, nascent BVs as shown here using a simple
in vivo assay.
Our data reveal that in lieu of a uniform, broadly multi-
potent, and equipotent class of ubiquitous ‘‘MSCs,’’ peri-
natal and postnatal assayable progenitors found in CB,
skeletal tissues, and skeletal muscle comprise a varied sys-
tem of tissue-specific progenitors. Each member of the sys-
tem is committed to a specific differentiation range. CB
mesenchymal progenitors are committed to cartilage and
bone formation, reminiscent of the potential of prenatal
skeletal progenitors to generate skeletal rudiments made
of cartilage and bone. Postnatal BM skeletal progenitors
are instead committed to bone and BM stroma formation,
but not to cartilage, mirroring an adult structure of skeletalFigure 7. In Vivo Transplantation of CD146+ ‘‘MSCs’’ Derived from
(A) Co-transplant of cell-surface GFP-labeled BM-derived progenitors
formation of an extensive network of capillary-like blood vessels (cB
microscopy and immunostaining, their wall was made by two cell laye
hCD34+ (red), and an outer, discontinuous layer of mural cells made by
8 weeks exhibited extensive maturation of the blood vessel (BV) wall
BVs (H&E staining). These vessels were functional as indicated by per
(RBCs, black arrow). The vessels were coated with a multilayer of a-S
illuminated by differential interference contrast microscopy to see the
and immunostaining, a multilayer of GFP+ cells surrounding hCD34+
50 mm, 60 mm, 80 mm, or 90 mm as indicated.
(B) Similar experiments with cell-surface GFP-labeled MU CD146+ prog
capillary lattice (cBV) at 3 weeks, which was less extensive than with B
by perfusion with host RBCs. As with BM cells, GFP-labeled MU cells
represent 20 mm, 25 mm, 40 mm, or 100 mm as indicated.
(C) Heterotopic co-transplantation of CB cells in Matrigel along with H
like BVs (cBV) at 3 weeks, which were functional and perfused by hos
wall was made by an inner continuous hCD34+ endothelial layer (red,
cells (green, white arrows) and an outer coat of chondrocytes and cart
the cartilage stain, Alcian blue), making these BVs a unique kind of ca
450 mm as indicated.segments. Myogenic and skeletogenic potential are mutu-
ally exclusive, as dictated by a specific set of master tran-
scriptional regulators.
Our data are consistent with recent studies showing that
in vivo, transplants of BM cells were able to form bone and
support marrow formation, while white adipose-derived
stromal cells (WAT), cells from umbilical cord (UC), and
skin fibroblasts (SF) were not (Kaltz et al., 2008; Reinisch
et al., 2015). Importantly, the ‘‘MSCs’’ derived from cord
blood (CB) used in our study must be clearly distinguished
from fibroblastic cells derived fromUC ‘‘MSCs’’ in the Rein-
isch study; UC cells fail to differentiate in vitro and in vivo
(Kaltz et al., 2008; Liedtke et al., 2016; Reinisch et al., 2015),
differ in their typical HOX expression pattern (Liedtke
et al., 2010, 2016), and have a different molecular tran-
scriptomic signature lacking relevant integrin-binding sia-
loprotein (IBSP) expression (Bosch et al., 2012). Differences
in our study include culture in 20% fetal bovine serum
(FBS) and use of a ceramic carrier that favors direct osteo-
genesis (no evidence of endochondral bone formation).
In Reinisch et al. (2015), BM cells were grown in 10% hu-
man platelet lysate and transplanted with aMatrigel equiv-
alent (In Vitro Vasculogenesis Assay Kit; Millipore), and
bone formed through an endochondral process. Another
study investigated expression of mRNAs by BM cells, WAT
cells, and CB cells at a multiclonal level (Ragni et al.,
2013). While the mRNA patterns between the cells types
were similar, a small number of highly differentially ex-
pressed mRNAs were identified, which could affect the
expression ofmany genes. Of note, in vitro osteogenic, adi-
pogenic, and chondrogenic differentiation assays were per-
formed in both of these studies, and significant differencesDifferent Tissues in Conjunction with HUVECs
in Matrigel (labeled as matrigel) along with HUVECs resulted in the
V) at 3 weeks as demonstrated by H&E staining. By fluorescence
rs: an inner endothelial layer as marked by the endothelial marker,
transplanted, GFP-tagged BM progenitors. Transplants harvested at
as indicated by the formation of thick-walled artery- and vein-like
fusion with host blood, as shown by the presence of red blood cells
MA+ cells demonstrated by immunohistochemistry (middle column
disc-shaped host RBCs in the vessels). By fluorescence microscopy
endothelial cells (red) were observed. Scale bars represent 40 mm,
enitors transplanted with HUVECs also resulted in the formation of a
M cells, but similarly well organized and functional, as demonstrated
were seen surrounding hCD34+ endothelial cells (red). Scale bars
UVECs resulted in the formation of an extensive network of capillary-
t RBCs (black arrows). By fluorescent immunohistochemistry, their
white arrows), coated by a subluminal layer of thin, hCD146+ mural
ilage matrix (labeled c as identified by H&E [light blue staining] and
rtilage-armored BV. Scale bars represent 30 mm, 60 mm, 200 mm, or
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were noted between the cell types. Nonetheless, the au-
thors of both papers concluded that an in vitromesengenic
process was at play in all cell types. However, in vitro ana-
lyses of osteogenic differentiation are not predictive of
in vivo transplantation (e.g., Phillips et al., 2014). For chon-
drogenesis, 3D cultures are needed to clearly see bona fide
chondrocytes lying in lacuna, surrounded by a matrix
that stains purple with toluidine blue (metachromasia) as
shown by Reinisch et al. (2015). Close examination of
this study suggests that there was little or no chondrogenic
differentiation ofWAT, UC, or SFs compared with BM cells.
In Ragni et al. (2013), chondrogenesis was difficult to assess
based on Alcian blue-stained 2D cultures and expression of
a limited number of markers, which is insufficient to
confirm chondrogenic differentiation.
Even if updated to equate ‘‘MSCs’’ with pericytes (Ca-
plan, 2008; Crisan et al., 2008), the widespread concept
of broadly and uniformly multipotent ‘‘MSCs’’ that are in-
variant in anatomical space and developmental time leaves
the developmental origin of such cells unaddressed, and in
fact collides with certain fundamental tenets of develop-
mental biology, such as the early segregation of inherent
osteogenic and myogenic potential into different lineages
(Bianco and Robey, 2015). Our data now reveal a simple
mechanism whereby assayable skeletogenic or myogenic
progenitors can be established in different tissues. As previ-
ously postulated (Bianco et al., 2008, 2013), we have now
directly shown that committed progenitors of different
origin and differentiation potential can physically asso-
ciate with nascent BV walls in an experimental assay, and
be recruited to a mural cell fate. In an earlier study, the
most robust contribution of grafted mesoderm progenitor
cells in quail chick chimeras was, in fact, to the adventitia
of BVs of any caliber (Minasi et al., 2002). In development,
somite-derived cells associate with, and are incorporated
into, the wall of the dorsal aorta (Esner et al., 2006). Peri-
cytes originate from the recruitment of non-endothelial,
mesenchymal cells to vascular walls (Armulik et al., 2011;
Hellstrom et al., 1999; Hirschi and D’Amore, 1996; Jain,
2003; Lindahl et al., 1997). Obviously, the same mecha-
nismmay operate in different tissues and at different devel-
opmental times. Generalmechanisms regulatingmural cell
recruitment have largely been elucidated, and provide the
background against which to seek additional determinants
operating in the retention of quiescent mesoderm progen-
itors in a vascular niche. CD146 itself may represent a
player in this scenario, consistent with its nature as a cell-
adhesion molecule (Shih, 1999), and with evidence pro-
vided here that its knockdown perturbs the establishment
of properly structured BVs in vivo.
The direct interaction of committed progenitors with
endothelial walls of nascent BV can be related to their
arrested proliferation and differentiation, leading to reten-910 Stem Cell Reports j Vol. 6 j 897–913 j June 14, 2016tion, within specific tissues, of a compartment of progeni-
tors with predefined commitment, and a potential for
further growth defined by their replicative history prior
to incorporation into BV walls. The long-known heteroge-
neity of clonogenic mesodermal progenitors (CFU-Fs) in
proliferative potential ex vivo might find in this view a
simple explanation.
Our data have additional implications of applied nature.
Prospective isolation of putative ‘‘MSCs’’ from different
tissues, based on the use of the minimal effective sur-
face phenotype CD34/CD45/CD146+ (Sacchetti et al.,
2007), leads to isolation of committed tissue-specific pro-
genitors, not of broadly multipotent, equivalent cells.
Hence, design of cell-therapy strategies for specific tissues
must remain cognizant of the specificity of the isolatable
progenitors. In fact, reliance on this specificity leads to
highly effective isolation of tissue-specific progenitors.
This is best illustrated by the case of skeletal muscle, where
we have shown that CD146+ cells are far more enriched in
spontaneously myogenic cells than previously identified
populations of putative non-satellite cell classes (Dellavalle
et al., 2007). Importantly, we have shown that these cells,
which do express the satellite lineage marker, PAX7, and
behave like satellite cells in in vitro and in vivo assays
(Montarras et al., 2005), may in fact represent subsets of
the same original population, recruited to distinct anatom-
ical niches based on distinct, local cell-cell interactions,
randomly directing individual progenitors to either the
surface of developing fibers (satellite cells) or the surface
of nascent BVs (myogenic pericytes, or else ectopic satellite
cells). Consistent with this hypothesis, proximity of one
anatomical locale to the other can amount, in fact, to less
than one cell diameter. However, it is also possible that
the pericytic MU CD146+ cells are more primitive than sat-
ellite cells based on the fact that they give rise to CD56+ sat-
ellite cells (Figure 5C). Also of note, MU CD146+ cells do
not coincide with PICs (interstitial populations of PW1+/
PAX7 cells; Mitchell et al., 2010), based on the fact that
MUCD146+ cells are PAX7+, or FAPs (fibro/adipogenic pro-
genitors) that cannot generate myofibers (Joe et al., 2010),
while MU CD146+ clearly do.
In summary, we have provided a rigorous analysis of
mesodermal progenitors isolated from perinatal and post-
natal tissues that reveals their inherent differentiation po-
tential. These data underscore the fact that a ubiquitous
‘‘MSC’’ with identical differentiation capacities does not
exist, and thus the ‘‘MSC’’ terminology should be aban-
doned for the sake of clarity. Furthermore, we have demon-
strated that irrespective of their inherent differences,
tissue-specificmesodermal progenitors are capable of being
recruited to a mural cell fate, providing a plausible mecha-
nism by which pericytes are formed, and how they serve as
a source of local stem/progenitor cells.
EXPERIMENTAL PROCEDURES
Cell Isolation and Culture
Samples were obtained with informed consent according to insti-
tutionally approved protocols. BM-, PE-, and CB-derived cells,
dermal fibroblasts, adipose-derived stromal cells, amniotic fluid
cells, and HUVECs were grown as described in Supplemental
Experimental Procedures.
For MU cells, normal muscle samples (1–30 3 102 mg) from 17
human adult patients (25–65 years old) were enzymatically disso-
ciated as described in Supplemental Experimental Procedures. The
resulting single-cell suspensionswere used to obtain cultures of un-
fractionated cells, or for sorting of CD146+ cells, CD146+/CD56+
cells, CD146+/CD34+ cells, or CD146+/ALP+ cells. Unsorted and
sorted cells were plated in basalmedium (aminimumessentialme-
dium [aMEM; Invitrogen] with 20% FBS [Invitrogen], 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin).
For non-clonal cultures, cells were seeded at 1.6 3 103–1.6 3 105
cells/cm2 in 75-cm2 flasks or in 100-mm dishes (Becton Dickin-
son). For multiclonal cultures (combining multiple colonies), cells
were seeded into 100-mmdishes at 1.6 cells/cm2, and formation of
discrete colonieswas scored after 14 days. Non-clonal cultureswere
passaged when subconfluent; multiclonal cultures were passaged
on day 14.Cell Sorting and Flow Cytometry
Surface markers were assessed using a FACSCalibur flow cytometer
with CellQuest software (BD Biosciences) as reported previously
(Sacchetti et al., 2007) with mouse anti-human monoclonal anti-
bodies (Table S7A) and isotype controls. CD146+, CD146+/
CD56+, CD146+/CD34+ cell subsets, and CD146+/ALP+ subsets
were separated using a FACSDIVAntageSE flow cytometer (BD Lab-
ware). CD146+, CD146+/CD56+, CD146+/CD34+, and CD146+/
ALP+ fractions were separated using a MiniMACS magnetic col-
umn separation unit (Miltenyi Biotec) according to the manufac-
turer’s instructions.Gene-Expression Profiling and Data Analysis
Total RNA was isolated from multiclonal cultures of CD146+ cell
populations from three independent cultures after 2 weeks of cul-
ture in basal medium (see above), and processed as described in
Supplemental Experimental Procedures. Raw data of gene-expres-
sion profiling were submitted to the GEO repository (GEO:
GSE69991).Gene Set Enrichment Analysis
GSEA was performed using GSEA software (http://www.
broadinstitute.org/gsea/index.jsp) (Subramanian et al., 2005) as
described in Supplemental Experimental Procedures.Colony-Forming Efficiency Assays
CFE assayswere performedwith different cell fractions obtained by
cell sorting. CD146+ cells were seeded in basal medium (see above)
at 1.6–3.3 cells/cm2, CD146+/CD34+ and CD146+/CD56 cells
were seeded at 1.6–8.3 cells/cm2, and CD146+/ALP+ were seeded
at 0.083–3.3 cells/cm2. CD146 (CD56+ or CD34+ or ALP+)unsorted cells were seeded at an equivalent or higher density
(1.6–1.6 3 105 cells/cm2) and grown under identical conditions.
After 14 days, CFEwas determined as themeannumber± SDof col-
onies (>50 cells)/102–105 cells initially plated. ALP cytochemistry
was done using naphthol-AS-phosphate as substrate and Fast
Blue BB as coupler.
In Vitro Differentiation Assays
Spontaneous myogenic differentiation was assessed by plating
cells onto Matrigel-coated dishes, with DMEM/2% horse serum,
or on plastic with aMEM/20% FBS at clonal density. After 7 days,
cultures were fixed and labeled for immunofluorescence with a
monoclonal antibody against striated MyHC. Myogenic efficiency
was estimated as the percentage of DAPI+ nuclei found within
myosin-positive myotubes. Fluorescence images were obtained us-
ing an Eclipse TE2000 Inverted Microscope (Nikon). Data were
compared by ANOVA.
In Vivo Transplantation Assays
All animal procedures were approved by the relevant institutional
committees.
Heterotopic Bone Formation
Constructs of test cells and osteoconductive material (hydroxyap-
atite/tricalcium phosphate [HA/TCP; Zimmer]) were transplanted
into the subcutaneous tissue of SCID/beige mice (CB17.Cg-
PrkdcscidLystbg-J/Crl; Charles River), using an established assay
(Krebsbach et al., 1997; Sacchetti et al., 2007).
Orthotopic Myogenesis
CTX model: MU- BM-, and CB-derived cell populations (1 3 106)
were injected intramuscularly into the left tibialis anterior of
2-month-old female SCID/beige mice injured 1 day earlier by an
intramuscular injection of cardiotoxin (CTX; Latoxan) (Dellavalle
et al., 2007). Muscles were examined 4 weeks following transplan-
tation. SCID/mdx model: MU- and BM-derived cell populations
were injected via the femoral artery of 2-month-old female SCID/
mdx dystrophic mice (C57BL/10ScSn-mdx/J; Jackson Laboratory)
as described by Dellavalle et al. (2007). Two injections of 5 3 105
cells at a 15-day interval were performed, and animals were eutha-
nized 15 days after the last injection (30 days in total). The injected
tibialis anterior muscles were analyzed for myogenic markers
by immunofluorescence, with uninjected contralateral muscles
serving as controls.
Heterotopic Differentiation, Matrigel
1 3 106 cells from multiclonal cultures of MU, BM, and CB cells
were suspended in 1 ml of Matrigel Growth Factor-Reduced (BD
Biosciences Labware), either alone ormixed with an equal number
of HUVECs (Cambrex). Aliquots (0.7 ml) were injected in the
subcutaneous tissue of the back of SCID/beige mice, and trans-
plants were harvested after 20 days. In some experiments, cells
from multiclonal cultures of MU and BM cells were transduced
with GFP-lentiviral vectors.
Lentiviral Vectors
Lentiviral vectors for GFP expression and CD146 silencing were
produced and used as described previously (Piersanti et al., 2010;
Sacchetti et al., 2007). Sorted CD146+ cells from BM and MU were
transduced with GFP-lentiviral vectors at anMOI of 5 and culturedStem Cell Reports j Vol. 6 j 897–913 j June 14, 2016 911
for 2 weeks in basal medium (see above) before use. CD146
silencing is described in Supplemental Experimental Procedures.
Immunohistochemistry Studies
Heterotopic and orthotopic transplants were processed as
described in Supplemental Experimental Procedures. All experi-
ments using mice were performed under institutionally approved
protocols. All primary antibodies used for immunolocalization
studies are listed in Table S7B.
RT-PCR
Conditions used in this study are described in Supplemental Exper-
imental Procedures, and primers are listed in Table S7C.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, and seven tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2016.05.011.
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